Drugs / Adsorbed tetanus vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT06360250 Background | Apr → Oct 2024 | tetanus | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 1 | NCT06607380 Comparator | Aug 2022 → Apr 2023 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adsorbed tetanus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360250 ↗ |
| Modality | Vaccine | “Adsorbed tetanus vaccine (TT)” NCT06360250 ↗ |
| Route | Intramuscular | “A single IM deltoid injection” NCT06607380 ↗ |